Navigation Links
MultiCell Technologies is Granted Stem Cell Patent
Date:5/31/2011

WOONSOCKET, R.I., May 31, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the issuance of U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease.  Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528.  

The patent describes methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function.  Patients who suffer from severe, irreversible liver disease for which other medical and surgical treatments have failed are often candidates for a liver transplant.  Liver stem cells which differentiate into functional mature hepatocytes could help to reconstitute a diseased liver, and may be an alternative approach to whole organ transplants for certain liver diseases.

"We are pleased the USPTO has agreed that our liver stem cells are indeed novel and may lead to important therapeutic applications," said W. Gerald Newmin, Chairman and Chief Executive Officer.  "Our efforts to better understand liver stem cell biology, and the role these cells play in chronic liver disease and primary hepatocellular carcinoma, is a major focus of the Company," Mr. Newmin stated.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell Technologies' expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the predicted size of the interventional cardiology and intravascular stent market and statements regarding the efficacy and safety of the Ideal™ BioStent.  MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and all our quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
2. MultiCell Technologies Launches New Web Site
3. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
4. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
5. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
6. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
7. TriLink BioTechnologies, Inc. Awarded European Patent for CleanAmp™ Primers
8. Vicor Technologies CEO David H. Fater to Present Live, Online at RetailInvestorConferences.com
9. Mind Technologies Inc. Developing Revolutionary EEG Brain Computer Interface
10. Patient Safety Technologies Reports First Quarter 2011 Results
11. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 Brain Cancer patients ... method at West Cancer Center . Optune™, ... to inhibit cancer cell replication causing death of cancer ... a decade to show a significant extension in overall ... patients. Currently, West Cancer Center is the only medical ...
(Date:2/11/2016)... 2016 Jeffrey Zucker , vice ... will present at this year,s Summit for Clinical Operations Executives ... Miami, FL. Zucker will discuss how ... execution, supporting SCOPE,s "Improving Site Study Activation and Performance" portion ... Feb. 25 at 11:05 a.m. --> ...
(Date:2/11/2016)... Ohio , Feb. 11, 2016  Community pharmacists ... increasing efficiency for the pharmacy through a custom-built medication ... Schieber , pharmacist and owner at Schieber Family ... "We can get a lot of patients enrolled in ... for everybody. It,s a win for the patient, and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article ... as a weight loss dietary supplement, is being recalled due to the discovery that ... because there is not a single supplement on the market proven to help people ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent feature ... procedures. Along with performing procedures, the magazine also highlights that Dr. Sadati has ... One of the most common procedures he performs is his natural facelift. “As ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The president ... DoD Military Health System but would shift more of the cost burden to military ... TRICARE-reform plan laid out in the defense budget as including limited quantifiable benefit fixes ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... surgery, dermatology and women’s health, is pleased to announce the promotions of Allison ... Partners sales team, Steve Catone to executive vice president of North American capital ...
(Date:2/11/2016)... Laurel, NJ (PRWEB) , ... February 11, 2016 ... ... announces the call for nominations seeking candidates for the Board of Commissioners. Individuals ... with passion, skills and experience with diversity of clinical practice settings and across ...
Breaking Medicine News(10 mins):